Adjuvant pembrolizumab prolongs relapse-free survival, when compared with placebo, in patients with resected, stage II melanoma.
Median OS was not reached for the T-VEC plus pembrolizumab arm and 49.2 months for the placebo plus pembrolizumab arm.
A retrospective study evaluated the effect of 5% imiquimod prior to Mohs surgery in patients with basal cell carcinoma.
Bacteroides intestinalis and Intestinibacter bartlettii were significantly enriched in patients who experienced severe toxicity.
Previous treatment with aPD-1 therapy or targeted molecular therapy is associated with a lower objective response rate to adoptive cell transfer of autologous tumor-infiltrating lymphocytes in metastatic melanoma.
The application is supported by data from the phase 2 IMCgp100-202 trial that assessed tebentafusp in 378 HLA-A*02:01-positive adults with previously untreated metastatic uveal melanoma.
How significant is the racial disparity in treating patients with skin cancer? Studies in recent years that suggest a troubling difference in the diagnosis and treatment some patients receive. We explore the significant impact this has on patient prognosis.
Female patients showed an enhanced rate of dermatologic adverse events with immune checkpoint inhibitor therapy for metastatic melanoma.
Researchers studied a total of 1903 cases of pediatric melanoma and patients were 54.4% female, the mean age was 12.4 years, and 89.8% were White.
Dermatologist-performed total body skin examinations (TBSEs) identify numerous cutaneous malignancies that might otherwise remain undiagnosed.